Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry.[when?] Company sales totalled 36.173 billon US$ in 2008. Currently,[when?] Novartis is the sixth largest pharmaceutical company in terms of revenue ($41.5 billion in 2009) with a profit margin of about 20%, which is the same as its industry competitors. Novartis profits were down by 31% from 2007 levels. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.
Source: Wikipedia
Campaign Finance
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.
Latest FEC Data
covers through committee's May 31, 2012 filing.-
Summary
overview of the committee's finances- Total Raised:
- $511,446
- Total Spent:
- $534,474
- Cash on Hand:
- $110,299
- Debts:
- $0
Standardized Donation Information
covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.-
Top Recipients
- Employee Color Block
- Individuals
- PAC Color Block
- PAC
-
Republicans vs. Democrats
in dollars -
State vs. Federal
in dollars -
Top PAC Recipients
- Employee Color Block
- Individuals
- PAC Color Block
- PAC
Lobbying
$6,809,948 SpentFigures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying On Behalf of Novartis AG
-
Names of Lobbyists
-
Firm Hired Amount Williams & Jensen $490,000 Capitol Hill Consulting Group $240,000 Law Offices of Frederick H Graefe $180,000 Nickles Group $180,000 Podesta Group $100,000 Ricchetti Inc $90,000 Ice Miller Strategies $70,000 Winning Strategies Washington $60,000 Bockorny Group $60,000 Cornerstone Government Affairs $60,000 -
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Fed Budget & Appropriations,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Trade,
- Taxes,
- Labor, Antitrust & Workplace,
- Government Issues,
- Defense,
- Medical Research & Clin Labs
-
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009
Regulations
24 Mentions; 5 SubmissionsAll data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Novartis AG" in public comments on proposed federal regulations.
-
Documents Submitted by the Organization
-
Mentions in Document Text
Contractor Misconduct
2 InstancesThis information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.
More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.
| Misconduct Type | Hired By | Incident | Year | Disposition | Penalty |
|---|---|---|---|---|---|
| Labor | None | Nationwide Wage and Hour Class Action Lawsuit | 2012 | Settlement | $99,170,000 |
| Antitrust | None | Pharmaceutical Industry Average Wholesale Price Litigation | 2011 | Settlement | $0 |
